HC Wainwright Boosts BioNTech (NASDAQ:BNTX) Price Target to $150.00

BioNTech (NASDAQ:BNTX) had its target price raised by research analysts at HC Wainwright from $113.00 to $150.00 in a report released on Monday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 24.69% from the stock’s previous close.

A number of other analysts have also weighed in on BNTX. Morgan Stanley raised shares of BioNTech from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $93.00 to $145.00 in a research note on Tuesday, September 24th. Jefferies Financial Group raised BioNTech from a “hold” rating to a “buy” rating and boosted their price target for the stock from $96.00 to $150.00 in a research report on Tuesday, September 17th. TD Cowen decreased their price objective on BioNTech from $98.00 to $85.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. UBS Group lifted their target price on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research note on Wednesday, September 18th. Finally, Bank of America increased their price target on shares of BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Five investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and a consensus target price of $131.92.

BioNTech Stock Performance

Shares of NASDAQ:BNTX opened at $120.30 on Monday. The firm’s 50 day simple moving average is $98.75 and its 200-day simple moving average is $92.81. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. BioNTech has a one year low of $76.53 and a one year high of $131.49. The firm has a market cap of $28.60 billion, a PE ratio of 240.60 and a beta of 0.24.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The firm had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. During the same quarter in the previous year, the business earned ($0.86) earnings per share. The company’s revenue for the quarter was down 23.3% compared to the same quarter last year. As a group, equities analysts predict that BioNTech will post -2.87 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Candriam S.C.A. increased its position in shares of BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after acquiring an additional 418,695 shares during the period. Discovery Capital Management LLC CT acquired a new position in shares of BioNTech in the second quarter valued at about $2,467,000. Goldman Sachs Group Inc. increased its holdings in shares of BioNTech by 17.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 182,878 shares of the company’s stock valued at $19,301,000 after purchasing an additional 26,777 shares during the period. Harding Loevner LP purchased a new position in shares of BioNTech in the fourth quarter worth about $410,984,000. Finally, Neuberger Berman Group LLC acquired a new stake in shares of BioNTech during the fourth quarter worth about $1,562,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.